Pioglitazone and non-alcoholic fatty liver

The effect of pioglitazone on the improvement of non-alcoholic fatty liver in obese patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210614051574N3

Enrollment

Registered

2021-08-07

Start date

2021-09-04

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: Patients in this group are examined for the degree of fatty liver and then for 4 months, in addition to dietary recommendations, will receive pioglitazone 15 mg tab

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age between 18 and 65 years Candidate for bariatric surgery Non-alcoholic fatty liver disease grade 3 Satisfaction with inclusion in the study

Exclusion criteria

Exclusion criteria: Daily consumption of more than 40 grams and 20 grams of alcohol for men and women, respectively Having other liver diseases Liver cancer Taking hepatotoxic drugs

Design outcomes

Primary

Measure	Time frame
Fatty liver grade. Timepoint: Before and 4 months after treatment. Method of measurement: Sonography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMasoud Sayadi

Esfahan University of Medical Sciences

parsa.alinezhad85@gmail.com+98 31 3668 0042

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026